Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.39 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.36 |
| ▸ | NHERF1 | O14745 | 3/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.35 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6707749 | 0.92 | GRIK1 (0.42) | GRIK1PLCG2PLA2G7LMNATP53 | |
| SCHEMBL6710278 | 0.92 | PARP14 (0.43) | GRIK1PLCG2PLA2G7NHERF1F11 | |
| SCHEMBL6713233 | 0.91 | GRIK1 (0.41) | GRIK1PLCG2PLA2G7NHERF1F11 | |
| SCHEMBL6713394 | 0.91 | PARP14 (0.42) | GRIK1PLCG2PLA2G7NHERF1STK33 | |
| SCHEMBL6709861 | 0.90 | GRIK1 (0.41) | GRIK1PLCG2NHERF1TP53POLB | |
| SCHEMBL6708770 | 0.90 | GRIK1 (0.41) | GRIK1PLCG2PLA2G7PTK2BLMNA | |
| SCHEMBL6710251 | 0.90 | PARP14 (0.35) | GRIK1PLCG2PLA2G7LMNATP53 | |
| SCHEMBL6711895 | 0.90 | PARP14 (0.44) | GRIK1PLCG2PLA2G7NHERF1F11 | |
| SCHEMBL6712543 | 0.89 | GRIK1 (0.43) | GRIK1PLCG2PLA2G7NHERF1F11 | |
| SCHEMBL6709877 | 0.89 | GRIK1 (0.43) | GRIK1PLCG2PLA2G7NHERF1F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | GRIK1 3885/4885PLCG2 4289/4885PLA2G7 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.